reference/31583218

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31583218

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	2141
issn	1535-7163 1538-8514
issueIdentifier	8
pageRange	2131-2141
publicationName	Molecular Cancer Therapeutics
startingPage	2131
bibliographicCitation	Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther. 2009 Aug;8(8):2131–41. doi: 10.1158/1535-7163.mct-08-1038. PMID: 19671750.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28957e55abc436b007480fe952b71727 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bebf7f4f0bb09d237dc3cd8feb0037a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_506a6d662010fd9a5d71bebcb147a917 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78999125dad28c33bc249363343bc290 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_68437b6ebf7dc8ee1ba24c45bf355e86 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b3a28fd55dc1539d8ff2867dd4241a46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_518f61326fe59c69980a7987b5098709 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dda4834b7902bf41950cbd595b54d770 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79ae728c9bf3feff0cf01b80b7fe8619 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d53268f44cb8012145e225a6a902462
date	2009-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/19671750 https://doi.org/10.1158/1535-7163.mct-08-1038
isPartOf	https://portal.issn.org/resource/ISSN/1535-7163 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30097 https://portal.issn.org/resource/ISSN/1538-8514
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2–positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib
discusses	http://id.nlm.nih.gov/mesh/M0028195 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0291428 http://id.nlm.nih.gov/mesh/M0473129 http://id.nlm.nih.gov/mesh/M0024780 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0291469 http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0456188 http://id.nlm.nih.gov/mesh/M0457532
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D047029Q000494 http://id.nlm.nih.gov/mesh/D018841Q000037 http://id.nlm.nih.gov/mesh/D047428Q000494 http://id.nlm.nih.gov/mesh/D016227Q000494 http://id.nlm.nih.gov/mesh/D018719Q000037 http://id.nlm.nih.gov/mesh/D000971Q000494
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D023041 http://id.nlm.nih.gov/mesh/D004357 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D018719Q000378 http://id.nlm.nih.gov/mesh/D045744 http://id.nlm.nih.gov/mesh/D000077341 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000068878 http://id.nlm.nih.gov/mesh/D000911Q000494 http://id.nlm.nih.gov/mesh/D004354 http://id.nlm.nih.gov/mesh/D018841Q000378 http://id.nlm.nih.gov/mesh/D011799Q000494
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fe0d872c4ea3e7d9f07488fc82841cc8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11685945 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_472b28cee6c37ce9d58de4aa1dc6d7ef http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cae1136973304226b6579fdacf6db996 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11534420 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID208908

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127494626

Total number of triples: 68.